Regen BioPharma Reports Stable Revenue but Increased Net Loss for Q2 2025

Regen BioPharma, Inc. reported its financial results for the three and six months ended March 31, 2025, revealing net revenues of $59,065 for the quarter and $118,130 for the half-year, consistent with the same periods in 2024. The revenue figures included $27,425 from related parties, specifically from a license agreement with Zander Therapeutics, Inc., and $31,640 from Oncology Pharma, Inc. for both periods. Despite stable revenue, the company experienced a net loss of $19,354 for the three months ended March 31, 2025, a significant improvement from a net loss of $122,454 in the same quarter of the previous year. However, for the six-month period, the net loss increased to $534,739 compared to $267,387 in 2024, primarily due to a derivative loss of $287,053 recognized in 2025.

Operating expenses for the three months ended March 31, 2025, totaled $172,414, up from $160,135 in the prior year, driven largely by increased consulting and professional fees, which rose to $136,566 from $93,400. For the six-month period, operating expenses decreased to $292,857 from $341,982 in 2024, reflecting a reduction in research and development costs, which were $0 in 2025 compared to $87,661 in 2024. The company’s total operating loss for the quarter was $113,349, compared to $101,071 in the previous year, while the six-month operating loss improved to $174,727 from $223,853.

In terms of operational developments, Regen BioPharma's working capital deficit increased to $5,716,131 as of March 31, 2025, from $5,235,105 at the end of September 2024, primarily due to an increase in derivative liabilities. The company reported cash of $1,761 at the end of the reporting period, a slight increase from $716 at the beginning of the period. The company’s cash flow from operating activities showed improvement, with a net cash used of $167,609 for the six months ended March 31, 2025, compared to $371,658 in the same period of 2024.

Looking ahead, Regen BioPharma continues to focus on the development of regenerative medical applications, although it acknowledges the need for additional funding to support its operations and development plans. The company has incurred significant operating losses and negative cash flows since its inception, raising substantial doubt about its ability to continue as a going concern without securing further capital. The management has indicated that it will seek additional working capital through the sale of equity and/or debt securities to sustain its operations and execute its business strategy.